PMID- 25906091
OWN - NLM
STAT- MEDLINE
DCOM- 20150626
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 94
IP  - 16
DP  - 2015 Apr
TI  - A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients 
      With Advanced Gastric Cancer.
PG  - e652
LID - 10.1097/MD.0000000000000652 [doi]
LID - e652
AB  - The aim of this study was to compare the efficacy and safety of S-1-based therapy 
      versus non-S-1-based therapy in advanced gastric cancer (AGC) patients.Eligible 
      studies stratifying objective response rate (ORR), progression-free survival 
      (PFS), overall survival (OS), and adverse events (AEs) in AGC patients were 
      identified from Embase, Pubmed, Cochrane Library, and China National Knowledge 
      Infrastructure databases. The STATA package (version 11.0) was used to pool the 
      data from the eligible studies.Fifteen studies with 2973 AGC cases, of which 1497 
      (50.4%) received S-1-based therapy and 1476 (49.6%) received non-S-1-based 
      therapy, were identified in the meta-analysis. AGC patients who had received 
      S-1-based therapy had a higher median OS, median PFS, and ORR than those who had 
      received 5-fluorouracil (FU)-based therapy (OS: hazard ratio [HR] 0.89, 95% 
      confidence interval [CI] 0.80-0.98, P = 0.015; PFS: HR 0.88, 95% CI 0.80-0.98, 
      P = 0.016; ORR: OR 1.25, 95% CI 1.08-1.45, P = 0.003, respectively). S-1-based 
      therapy had similar efficacy to capecitabine-based therapy in terms of median OS 
      (HR 1.14, 95% CI 0.91-1.41, P = 0.253), median PFS (HR 1.01, 95% CI 0.82-1.25, 
      P = 0.927), and ORR (OR 0.84, 95% CI 0.63-1.12, P = 0.226). Subgroup analysis for 
      grade 3 to 4 toxicity showed higher incidence of neutropenia (relative risk 
      [RR] = 0.827, P = 0.006), nausea (RR = 0.808, P = 0.040), and lower diarrhea 
      (RR = 1.716, P = 0.012) in 5-FU-based arm, and higher diarrhea (RR = 0.386, 
      P = 0.007) in capecitabine-based arm.S-1-based chemotherapy is favorable to AGC 
      patients with better clinical benefit than 5-FU-based chemotherapy and with 
      equivalent antitumor compare with capecitabine-based therapy.
FAU - Wu, Fang-Lan
AU  - Wu FL
AD  - From the Hospital Quality Management Office (F-LW); Department of Endocrinology 
      (D-CL, A-MZ, XY, JZ, H-QH); Department of Thoracic and Cardiovascular Surgery 
      (Y-PY); Outpatient Department (J-JH, H-YZ); Department of Gastroenterology 
      (D-KJ); and Department of Infectious Disease, First Affiliated Hospital of 
      Guangxi Medical University, Nanning, 530021, Guangxi, China (M-WC).
FAU - Lu, De-Cheng
AU  - Lu DC
FAU - Ying, Yan-Ping
AU  - Ying YP
FAU - Huang, Jin-Jiao
AU  - Huang JJ
FAU - Zhou, Ai-Min
AU  - Zhou AM
FAU - Jiang, Dun-Ke
AU  - Jiang DK
FAU - Chen, Mao-Wei
AU  - Chen MW
FAU - Yang, Xi
AU  - Yang X
FAU - Zhou, Jia
AU  - Zhou J
FAU - Huang, Hui-Qiao
AU  - Huang HQ
FAU - Zeng, Hong-Yan
AU  - Zeng HY
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drug Combinations)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Capecitabine
MH  - China
MH  - Clinical Trials as Topic
MH  - Deoxycytidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Disease-Free Survival
MH  - Drug Combinations
MH  - Female
MH  - Fluorouracil/adverse effects/*analogs & derivatives/*therapeutic use
MH  - Humans
MH  - Male
MH  - Oxonic Acid/adverse effects/*therapeutic use
MH  - Severity of Illness Index
MH  - Stomach Neoplasms/*drug therapy/*mortality
MH  - Tegafur/adverse effects/*therapeutic use
PMC - PMC4602687
COIS- The authors declare that they have no conflict of interest.
EDAT- 2015/04/24 06:00
MHDA- 2015/06/27 06:00
PMCR- 2015/04/24
CRDT- 2015/04/24 06:00
PHST- 2015/04/24 06:00 [entrez]
PHST- 2015/04/24 06:00 [pubmed]
PHST- 2015/06/27 06:00 [medline]
PHST- 2015/04/24 00:00 [pmc-release]
AID - 00005792-201504040-00002 [pii]
AID - 10.1097/MD.0000000000000652 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2015 Apr;94(16):e652. doi: 10.1097/MD.0000000000000652.